Demonstration of an Interferon Gamma-dependent Tumor Surveillance System in Immunocompetent Mice

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1998 Jun 24

PMID 9636188

Citations 532

Authors

D H Kaplan

V Shankaran

A S Dighe

E STOCKERT

M Aguet

L J Old

R D Schreiber

Affiliations

Soon will be listed here.

Abstract

This study demonstrates that endogenously produced interferon gamma (IFN-gamma) forms the basis of a tumor surveillance system that controls development of both chemically induced and spontaneously arising tumors in mice. Compared with wild-type mice, mice lacking sensitivity to either IFN-gamma (i.e., IFN-gamma receptor-deficient mice) or all IFN family members (i.e., Stat1-deficient mice) developed tumors more rapidly and with greater frequency when challenged with different doses of the chemical carcinogen methylcholanthrene. In addition, IFN-gamma-insensitive mice developed tumors more rapidly than wild-type mice when bred onto a background deficient in the p53 tumor-suppressor gene. IFN-gamma-insensitive p53(-/-) mice also developed a broader spectrum of tumors compared with mice lacking p53 alone. Using tumor cells derived from methylcholanthrene-treated IFN-gamma-insensitive mice, we found IFN-gamma's actions to be mediated at least partly through its direct effects on the tumor cell leading to enhanced tumor cell immunogenicity. The importance and generality of this system is evidenced by the finding that certain types of human tumors become selectively unresponsive to IFN-gamma. Thus, IFN-gamma forms the basis of an extrinsic tumor-suppressor mechanism in immunocompetent hosts.

Citing Articles

STAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis.

Chen Y, Wang D, Luo H, Tan M, Wang Q, Wu X Mol Cell Biochem. 2025; .

PMID: 40087208 DOI: 10.1007/s11010-025-05240-z.

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma.

Saevarsson T, de Lomana A, Sanchez O, van Esch V, Ragnarsson G, Brynjolfsson S Cell Commun Signal. 2024; 22(1):618.

PMID: 39736644 PMC: 11687009. DOI: 10.1186/s12964-024-01963-6.

Identification of Gene Regulatory Networks Associated with Breast Cancer Patient Survival Using an Interpretable Deep Neural Network Model.

Wang X, Sarangi V, Wickland D, Li S, Chen D, Thompson E Expert Syst Appl. 2024; 262.

PMID: 39676894 PMC: 11643596. DOI: 10.1016/j.eswa.2024.125632.

Cytokines in cancer.

Kureshi C, Dougan S Cancer Cell. 2024; 43(1):15-35.

PMID: 39672170 PMC: 11841838. DOI: 10.1016/j.ccell.2024.11.011.

Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy.

Hou B, Ye J, Huang L, Cheng W, Chen F, Zhou H Sci Adv. 2024; 10(46):eadq3940.

PMID: 39546592 PMC: 11567003. DOI: 10.1126/sciadv.adq3940.

References

Burnet F . The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27. DOI: 10.1159/000386035. View

Boehm U, Klamp T, Groot M, Howard J . Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15:749-95. DOI: 10.1146/annurev.immunol.15.1.749. View

Stutman O . Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst. 1979; 62(2):353-8. View

Schreiber R, Hicks L, Celada A, Buchmeier N, Gray P . Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol. 1985; 134(3):1609-18. View

Schreiber H, Ward P, Rowley D, Stauss H . Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83. DOI: 10.1146/annurev.iy.06.040188.002341. View

Farrar M, Schreiber R . Identification of two regions within the cytoplasmic domain of the human interferon-gamma receptor required for function. J Biol Chem. 1991; 266(29):19626-35. View

Rogers H, Sheehan K, Brunt L, Dower S, UNANUE E, Schreiber R . Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sci U S A. 1992; 89(3):1011-5. PMC: 48375. DOI: 10.1073/pnas.89.3.1011. View

Rodig S, Meraz M, White J, Lampe P, Riley J, Arthur C . Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998; 93(3):373-83. DOI: 10.1016/s0092-8674(00)81166-6. View

Parganas E, Wang D, Stravopodis D, Topham D, Marine J, Teglund S . Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3):385-95. DOI: 10.1016/s0092-8674(00)81167-8. View

10.

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

11.

Urban J, Schreiber H . Tumor antigens. Annu Rev Immunol. 1992; 10:617-44. DOI: 10.1146/annurev.iy.10.040192.003153. View

12.

Dalton D, Keshav S, Figari I, Bradley A, Stewart T . Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993; 259(5102):1739-42. DOI: 10.1126/science.8456300. View

13.

Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R . Immune response in mice that lack the interferon-gamma receptor. Science. 1993; 259(5102):1742-5. DOI: 10.1126/science.8456301. View

14.

Farrar M, Schreiber R . The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993; 11:571-611. DOI: 10.1146/annurev.iy.11.040193.003035. View

15.

Harvey M, McArthur M, Montgomery Jr C, Butel J, Bradley A, Donehower L . Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993; 5(3):225-9. DOI: 10.1038/ng1193-225. View

16.

Darnell Jr J, Kerr I, Stark G . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. DOI: 10.1126/science.8197455. View

17.

Scanlan M, Raj B, Calvo B, Garin-Chesa P, Healey J, Old L . Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994; 91(12):5657-61. PMC: 44055. DOI: 10.1073/pnas.91.12.5657. View

18.

Boon T, Cerottini J, Van den Eynde B, van der Bruggen P, Van Pel A . Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12:337-65. DOI: 10.1146/annurev.iy.12.040194.002005. View

19.

Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R . Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4(1):1-7. DOI: 10.1016/s0960-9822(00)00002-6. View

20.

Dighe A, Richards E, Old L, Schreiber R . Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994; 1(6):447-56. DOI: 10.1016/1074-7613(94)90087-6. View